CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
About Us
Overview
Our work in Biosimilars
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Our Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Our Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Investors
Newsroom
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
Press Releases 2022
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2022
Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
Thu, 22-Dec-2022
Posted by: Biocon Biologics
No Comments
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Mon, 05-Dec-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Tue, 29-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
Tue, 15-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
Fri, 11-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine
Fri, 04-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
Fri, 05-Aug-2022
Posted by: Biocon Biologics
No Comments
Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%
Wed, 27-Jul-2022
Posted by: Biocon Biologics
No Comments
University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre
Thu, 09-Jun-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
Thu, 19-May-2022
Posted by: Biocon Biologics
No Comments
1
2